ID: ALA603715

Max Phase: Preclinical

Molecular Formula: C16H17ClN5O7PS

Molecular Weight: 489.83

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1ncnc2c1nc(Sc1ccc(Cl)cc1)n2C1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C16H17ClN5O7PS/c17-7-1-3-8(4-2-7)31-16-21-10-13(18)19-6-20-14(10)22(16)15-12(24)11(23)9(29-15)5-28-30(25,26)27/h1-4,6,9,11-12,15,23-24H,5H2,(H2,18,19,20)(H2,25,26,27)/t9-,11-,12-,15?/m1/s1

Standard InChI Key:  FAGBMJWRFRHMCM-FJFSNTMWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 489.83

Molecular Weight (Monoisotopic): 489.0275

AlogP: 0.94

#Rotatable Bonds: 6

Polar Surface Area: 186.07

Molecular Species: ACID

HBA: 11

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 1.22

CX Basic pKa: 4.59

CX LogP: -0.99

CX LogD: -2.27

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.31

Np Likeness Score: 0.10

References

1. Skibo EB, Meyer RB..  (1981)  Inhibition of inosinic acid dehydrogenase by 8-substituted purine nucleotides.,  24  (10): [PMID:6120232] [10.1021/jm00142a007]

2. Beres J, Bentrude WG, Kruppa G, McKernan PA, Robins RK..  (1985)  Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.,  28  (4): [PMID:2984417] [10.1021/jm00382a005]

Source

Source(1):

• Scientific Literature